Phase II intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma

Mikael J. Kajanti, Seppo O. Pyrhönen
{"title":"Phase II intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma","authors":"Mikael J. Kajanti,&nbsp;Seppo O. Pyrhönen","doi":"10.1016/0277-5379(91)90428-G","DOIUrl":null,"url":null,"abstract":"<div><p>Between August 1986 and September 1990, 22 previously untreated non-cirrhotic patients with measurable unresectable primary liver cancer were treated every 4 weeks with a combination of epirubicin and 5-fluorouracil. The dose of epirubicin was escalated; the starting dose was 40 mg/m<sup>2</sup>, the second dose was 50 mg/m<sup>2</sup> and thereafter 60 mg/m<sup>2</sup> during subsequent cycles. The dose of 5-fluorouracil was always 800 mg/m<sup>2</sup>. Objective response rate was 14%. Most of the patients experienced only mild haematological toxicity, and no other dose limiting toxicity was observed. Nonetheless, increasing the dose would probably not have increased the response rate.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90428-G","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190428G","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8

Abstract

Between August 1986 and September 1990, 22 previously untreated non-cirrhotic patients with measurable unresectable primary liver cancer were treated every 4 weeks with a combination of epirubicin and 5-fluorouracil. The dose of epirubicin was escalated; the starting dose was 40 mg/m2, the second dose was 50 mg/m2 and thereafter 60 mg/m2 during subsequent cycles. The dose of 5-fluorouracil was always 800 mg/m2. Objective response rate was 14%. Most of the patients experienced only mild haematological toxicity, and no other dose limiting toxicity was observed. Nonetheless, increasing the dose would probably not have increased the response rate.

表柔比星与5-氟尿嘧啶联合静脉注射治疗晚期肝癌的II期研究
在1986年8月至1990年9月期间,22名未接受治疗的非肝硬化不可切除原发性肝癌患者每4周接受一次表柔比星和5-氟尿嘧啶联合治疗。表柔比星的剂量逐渐增加;开始剂量为40 mg/m2,第二次剂量为50 mg/m2,随后的周期为60 mg/m2。5-氟尿嘧啶剂量始终为800 mg/m2。客观有效率为14%。大多数患者仅出现轻度血液学毒性,未观察到其他剂量限制性毒性。尽管如此,增加剂量可能不会增加反应率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信